INGN 225

Identification

Name
INGN 225
Accession Number
DB05325
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

INGN 225 is a therapeutic consisting of a cancer patient's own immune cells treated with an adenovector carrying the human p53 gene, Ad-p53. INGN 225 is currently in Phase 1/2 trials in patients with small cell lung cancer and breast cancer.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Categories
UNII
Not Available
CAS number
Not Available

Pharmacology

Indication

Investigated for use/treatment in breast cancer, head and neck cancer, and lung cancer.

Pharmacodynamics

INGN 225 uses the p53 tumor suppressor in a different manner than ADVEXIN to create a molecular immunotherapy for cancer that stimulates a particular type of immune system cell known as a dendritic cell. Testing has shown that the human immune system can recognize and kill tumors after treatment with dendritic cells stimulated by the p53 tumor suppressor, which suggests this therapy could have broad utility as a treatment for solid tumors. INGN 225 may also sensitize tumors to the effects of platinum and taxane chemotherapies.

Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with INGN 225.
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with INGN 225.
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with INGN 225.
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with INGN 225.
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with INGN 225.
AbetimusThe risk or severity of adverse effects can be increased when Abetimus is combined with INGN 225.
AbituzumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Abituzumab.
ActeosideThe risk or severity of adverse effects can be increased when Acteoside is combined with INGN 225.
AdalimumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Adalimumab.
AdecatumumabThe therapeutic efficacy of INGN 225 can be decreased when used in combination with Adecatumumab.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910082

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on November 18, 2007 11:23 / Updated on October 01, 2018 14:00